Jazz Pharmaceuticals plc (JAZZ)
NASDAQ: JAZZ · IEX Real-Time Price · USD
110.31
-0.44 (-0.40%)
At close: May 1, 2024, 4:00 PM
107.90
-2.41 (-2.18%)
After-hours: May 1, 2024, 6:27 PM EDT
Jazz Pharmaceuticals Employees
Jazz Pharmaceuticals had 2,800 employees on December 31, 2023. The number of employees did not change compared to the previous year.
Employees
2,800
Change (1Y)
n/a
Growth (1Y)
n/a
Revenue / Employee
$1,369,359
Profits / Employee
$148,154
Market Cap
6.88B
Employees Chart
Employees History
Date | Employees | Change | Growth |
---|---|---|---|
Dec 31, 2023 | 2,800 | 0 | - |
Dec 31, 2022 | 2,800 | -400 | -12.50% |
Dec 31, 2021 | 3,200 | 1,260 | 64.95% |
Dec 31, 2020 | 1,940 | 320 | 19.75% |
Dec 31, 2019 | 1,620 | 260 | 19.12% |
Dec 31, 2018 | 1,360 | 150 | 12.40% |
Dec 31, 2017 | 1,210 | 170 | 16.35% |
Dec 31, 2016 | 1,040 | 130 | 14.29% |
Dec 31, 2015 | 910 | 40 | 4.60% |
Dec 31, 2014 | 870 | 60 | 7.41% |
Dec 31, 2013 | 810 | 200 | 32.79% |
Dec 31, 2012 | 610 | 179 | 41.53% |
Dec 31, 2011 | 431 | 189 | 78.10% |
Dec 31, 2010 | 242 | 14 | 6.14% |
Dec 31, 2009 | 228 | 12 | 5.56% |
Dec 31, 2008 | 216 | -193 | -47.19% |
Dec 31, 2007 | 409 | 224 | 121.08% |
Dec 31, 2007 | 185 | - | - |
Sources: Annual number of employees according to filings submitted to the U.S. Securities and Exchange Commission (SEC). Data is also manually gathered from company press releases, IPO filings, and other official sources.
Related Stocks
Company Name | Employees |
---|---|
The Ensign Group | 35,300 |
Acadia Healthcare Company | 23,500 |
Elanco Animal Health | 9,800 |
Globus Medical | 5,000 |
Masimo | 3,800 |
HealthEquity | 3,150 |
Exelixis | 1,310 |
Inspire Medical Systems | 1,011 |
JAZZ News
- 3 hours ago - Jazz Pharmaceuticals to Participate in the BofA Securities 2024 Health Care Conference - PRNewsWire
- 3 hours ago - Jazz Pharmaceuticals Announces First Quarter 2024 Financial Results and Affirms 2024 Financial Guidance - PRNewsWire
- 7 days ago - Jazz Pharmaceuticals to Present Data Across Growing Oncology Pipeline and Portfolio at ASCO 2024 - PRNewsWire
- 14 days ago - Jazz Pharmaceuticals to Report 2024 First Quarter Financial Results on May 1, 2024 - PRNewsWire
- 21 days ago - Jazz Pharmaceuticals to Showcase Expansive Neuroscience Portfolio at American Academy of Neurology Annual Meeting - PRNewsWire
- 4 weeks ago - Jazz Pharmaceuticals Completes Zanidatamab Biologics License Application for Previously Treated HER2-Positive Metastatic Biliary Tract Cancer - PRNewsWire
- 7 weeks ago - Jazz Pharmaceuticals to Host Virtual Zanidatamab R&D Day on Tuesday, March 19, 2024 - PRNewsWire
- 2 months ago - Jazz Pharmaceuticals Announces Full Year and Fourth Quarter 2023 Financial Results and Provides 2024 Financial Guidance - PRNewsWire